Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

SINOVAC BIOTECH LTD.

(SVA)
  Report
SummaryQuotesChartsNewsCalendarCompanyFinancials 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Sinovac Biotech : COVID-19 booster shots should follow after China inoculates more -state media

08/24/2021 | 04:36am EDT

BEIJING, Aug 24 (Reuters) - COVID-19 booster shots should become available in China after the country vaccinates more people to provide broader protection against the disease, a senior executive at a Sinopharm unit responsible for developing COVID-19 vaccines told state media.

While the World Health Organization has said current data does not indicate booster shots are needed, several countries have approved them amid resurgent infections and concerns of waning vaccine protection over time, especially against the more infectious Delta variant of the coronavirus.

Zhang Yuntao, vice president at Sinopharm unit China National Biotec Group (CNBG), said that it is proper to make booster shots available in China after "all people who should be vaccinated are vaccinated," according to an interview with the Global Times published late on Monday.

He said the priority for booster shots should be given to people older than 60 who showed weaker immune responses to vaccines compared with younger people in clinical trials.

Employees at restaurants and those working in aviation and delivery industries should also be prioritised, he said.

China has fully vaccinated around 55% of its population as of Aug. 12, using several locally developed shots including two-dose vaccines from Sinopharm and Sinovac Biotech.

The two companies said studies have showed that injecting a third dose led to a significant increase in antibodies, which faded over time after a two-course regimen.

A lab study showed antibodies triggered by the Sinovac shot declined below a key threshold from around six months after a second dose for most recipients. (Reporting by Roxanne Liu and Ryan Woo; Editing by Miyoung Kim and Christian Schmollinger)


ę Reuters 2021
All news about SINOVAC BIOTECH LTD.
10/06SINOVAC BIOTECH : Pfizer study to vaccinate whole Brazilian town against COVID-19
RE
10/01SINOVAC BIOTECH : Malaysia approves Sinovac's COVID-19 vaccine for ages 12 to 17
RE
09/29SINOVAC BIOTECH : Rebuffed by Bolsonaro, Brazil medical institute to sell vaccines abroad
RE
09/24CANSINO BIOLOGICS : CanSinoBIO's COVID vaccine, tested at lower dosage, safe for children ..
RE
09/22SINOVAC BIOTECH : Thailand delays plan to re-open cities to tourists until November
RE
09/15INDONESIA IN TALKS WITH WHO TO BECOM : minister
RE
09/09SINOVAC BIOTECH : Says its New Research Shows Third Dose if its COVID-19 Vaccine More Effe..
MT
09/09SINOVAC BIOTECH : New Research on SINOVAC's COVID-19 Vaccine Shows Third Dose More Effecti..
BU
09/08SINOVAC BIOTECH : Announces COVID-19 Vaccine Approved for Emergency Use in Chile for Child..
BU
09/07SINOVAC BIOTECH : Mixing CanSinoBIO, Sinovac COVID shots induces stronger response than Si..
RE
More news
Financials (USD)
Sales 2020 511 M - -
Net income 2020 110 M - -
Net cash 2020 1 040 M - -
P/E ratio 2020 6,66x
Yield 2020 -
Capitalization 642 M 642 M -
EV / Sales 2019 1,86x
EV / Sales 2020 -0,78x
Nbr of Employees 1 959
Free-Float 33,5%
Chart SINOVAC BIOTECH LTD.
Duration : Period :
Sinovac Biotech Ltd. Technical Analysis Chart | SVA | AGP8696W1045 | MarketScreener
Income Statement Evolution
Managers and Directors
Wei Dong Yin Chairman, President, CEO, Secretary & MD
Nan Wang CFO & Vice President-Business Development
Qiang Gao Chief Operating Officer & Vice President
Yuk Lam Lo Independent Director
Jian Li Independent Director
Sector and Competitors
1st jan.Capi. (M$)
SINOVAC BIOTECH LTD.0.00%642
CSL LIMITED5.08%100 638
WUXI BIOLOGICS (CAYMAN) INC.6.42%59 673
SAMSUNG BIOLOGICS CO.,LTD.5.21%48 619
BIOGEN INC.16.50%41 907
ALEXION PHARMACEUTICALS, INC.0.00%40 336